Oral Mucosal Immunotherapy safer, convenient option for peanut allergy, finds study

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-03-04T00:30:44+05:30 | Updated On 4 March 2024 12:31 AM IST

Intrommune Therapeutics has been revolutionizing food allergy treatment and it has recently unveiled significant data that supports Oral Mucosal Immunotherapy (OMIT) as a promising new avenue for treating food allergies, particularly peanut allergies.

OMIT is an investigational treatment that delivers allergenic proteins via a specially formulated toothpaste by offering a convenient alternative to existing therapies. The key highlights of this research about OMIT to safely and effectively treat patients with food allergies were presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting 2024.

The findings from this presentation include a statistically significant increase in IgG4 levels and a decrease in the IgE/IgG4 ratio by indicating an immunologic response in active patients. The patients who initially failed an Oral Food Challenge (OFC) to a certain amount of peanut protein showed improved tolerance levels after OMIT treatment.

Dr. William Berger, the Introimmune consultant emphasized the significance of OMIT in addressing the limited options available for patients with food allergies. Unlike existing treatments, OMIT offers a safer and more convenient approach that marks a significant advancement in food allergy management. The results of this Phase 1 OMEGA Clinical Study enrolled a total of 32 adults with peanut allergies which unveiled the potential of OMIT as a potential therapy. The study was conducted under rigorous protocols and regulatory oversight and demonstrated the safety and efficacy of INT301, the lead product of Intrommune.

The food allergies affect millions worldwide, with peanut allergies posing significant risks due to accidental exposures. The OMIT platform of Intrommune presents a promising solution by leveraging patented biochemical processes to desensitize patients to allergenic proteins gradually. With food allergy management primarily centered on avoidance, OMIT represents the imperative breakthrough in the field.

Source:

Therapeutics, I. (2024, February 22). Intrommune therapeutics presents supporting data introducing a new form of food allergy treatment. Intrommune Therapeutics. https://www.globenewswire.com/news-release/2024/02/22/2833802/0/en/Intrommune-Therapeutics-Presents-Supporting-Data-Introducing-a-New-Form-of-Food-Allergy-Treatment.html

American Academy of Allergy Asthma and Immunology Annual Scientific MeetingOral mucosal immunotherapyPeanut allergies

Source : American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751